What is Verity Software House?
Verity Software House operates at the intersection of advanced computational biology and clinical research, providing a robust suite of cytometry software solutions. Their flagship product portfolio, which includes ModFit LT, WinList, and GemStone, serves as the industry standard for DNA cell-cycle analysis and complex flow and mass cytometry data processing. By delivering automated, high-fidelity analysis, the company addresses the critical needs of researchers and laboratory professionals who require reliable, reproducible results in high-throughput environments. The firm maintains a strong market position by prioritizing continuous software iteration and user-centric design, ensuring that their tools remain indispensable for modern diagnostic and experimental workflows.
How much funding has Verity Software House raised?
Verity Software House has raised a total of $60K across 1 funding round:
Debt
$60K
Debt (2021): $60K with participation from PPP
Key Investors in Verity Software House
PPP
Public-Private Partnership
What's next for Verity Software House?
With the recent infusion of capital, Verity Software House is poised to scale its operational infrastructure and broaden its research and development capabilities. The strategic focus will likely shift toward enhancing the automation features of their existing software suite and potentially exploring new frontiers in mass cytometry data interpretation. As the company navigates this growth phase, the emphasis remains on maintaining technical superiority while expanding its footprint in global research markets. This financing round provides the necessary runway to solidify their competitive advantage, ensuring that Verity Software House continues to lead in the provision of sophisticated analytical software for the global cytometry community.
See full Verity Software House company page
